Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer

Cancer Science

Volumn 105, Issue 12, 2014, Pages 1584-1590

  Gemma, Akihiko ^a   Kudoh, Shoji ^b   Ando, Masahiko ^c   Ohe, Yuichiro ^d   Nakagawa, Kazuhiko ^e   Johkoh, Takeshi ^f   Yamazaki, Naoya ^d   Arakawa, Hiroaki ^g   Inoue, Yoshikazu ^h   Ebina, Masahito ⁱ   Kusumoto, Masahiko ^j   Kuwano, Kazuyoshi ^k   Sakai, Fumikazu ^l   Taniguchi, Hiroyuki ^m   Fukuda, Yuh ⁿ   Seki, Akihiro ^o   Ishii, Tadashi ^o   Fukuoka, Masahiro ^p  

^a NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUJUJI HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^g DOKKYO MEDICAL UNIVERSITY   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

ⁱ Tohoku Medical and Pharmaceutical University Hospital   (Japan)

^j NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^k JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^m TOSEI GENERAL HOSPITAL   (Japan)

ⁿ Itabashi Chuo Medical Center   (Japan)

^o CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^p Izumi Municipal Hospital   (Japan)

more..

Author keywords

Erlotinib; Interstitial lung disease; Japanese; Non small cell lung cancer; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; QUINAZOLINE DERIVATIVE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPLICATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 4 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84917734552     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12550     Document Type: Article

References (13)

1. Shepherd F, Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005; 353: 123-32.
2. Kubota K, Nishiwaki Y, Tamura T et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008; 3: 1439-45.
3. Takahashi T, Yamamoto N, Nukiwa T et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2010; 30: 557-63.
4. Yamamoto N, Horiike A, Fujisaka Y et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2008; 61: 489-96.
5. Yoshida S. The results of gefitinib prospective investigation. Med Drug J 2005; 41: 772-89.
6. Kudoh S, Kato H, Nishiwaki Y et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 117: 1348-57.
7. Hotta K, Kiura K, Tabata M et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005; 11: 417-24.
8. Hotta K, Kiura K, Takigawa N et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol 2010; 5: 179-84.
9. Nakagawa K, Kudoh S, Ohe Y et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 2012; 7: 1296-303.
10. Inoue Y, Fukuoka M, Kudoh S et al. Tarceva tablet non-small-cell lung cancer special drug use-results survey final analysis about targeted numbers (3000 pts). Proc Japan Lung Cancer Society 2010; 50: 0-184.
11. Travis W, Costabel U, Hansell D et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-48.
12. Collard H, Moore B, Flaherty K et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-43.
13. Azuma A, Hagiwara K, Kudoh S. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients. Am J Respir Crit Care Med 2008; 177: 1397-8.